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Objective: To review the role of diagnostic laparoscopy (DL) for staging of malignant diseases of the liver
and biliary tract.
Methodology: Critical review of the current literature.
Results: Analysis of the utility of DL in hepatobiliary cancers depends on several criteria, particularly in the
era of high quality prelaparotomy and pre-DL imaging. Selection criteria for DL, selection criteria for resection,
definition of resectability, patterns of intra- and extrahepatic spread, association with underlying liver disease
and frequency of indications for palliative laparotomy impact the utility of DL depending on the disease
studied.
Conclusions: DL has a very limited role for staging patients with colorectal liver metastases as a result of
expanding definitions of resectability, multistage approaches to bilateral metastases, and methods to increase
resectability such as portal vein embolization and preoperative chemotherapy. For hepatocellular carcinoma,
DL can be useful for staging patients with advanced tumours and cirrhosis, and might have an emerging role
for the evaluation of transplant candidates with equivocal imaging findings. For biliary cancers, DL is indicated
for patients with advanced stage hilar cholangiocarcinoma and gall bladder carcinoma.
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Introduction
As early as the 1950s, laparoscopy was considered a
means to aid in the diagnosis of pathology in the liver.1
In the past 10 years, the role for diagnostic laparos-
copy (DL) in the diagnosis and staging of hepatobil-
iary malignancy has evolved, particularly in the setting
of high-quality imaging with computed tomography
(CT) and magnetic resonance imaging (MRI). DL has
been pursued as a staging modality, largely because
it compliments these cross-sectional imaging studies,
permits direct inspection of peritoneal surfaces,
including the liver surface, and enables laparoscopic
ultrasound (LUS) of the liver to further characterize
hepatic parenchyma and intraparenchymal abnormal-
ities in the liver. In addition, DL can facilitate patholog-
ical diagnosis of intra- and extrahepatic abnormalities.
Primary hepatic malignancies, primary biliary malig-
nancies and colorectal metastases to the liver are
three major categories of malignant disease for which
hepatic resection is the primary therapeutic modality.
Each disease presents different staging problems with
regards to diagnosis, different definitions of resectabil-
ity, different associations with underlying liver disease,
and different patterns of intrahepatic and extrahepatic
spread. Furthermore, the sensitivity and specificity of
preoperative imaging and DL/LUS to detect these
problems differs. Thus, despite some overlap, the indi-
cations for DL for each disease type must be consid-
ered separately.
Analysis of data regarding the role of DL in staging
hepatobiliary malignancies is further hindered by the
absence of Category 1 evidence (data based on pro-
spective randomized trials). Although Category 2 and
3 evidence infers that laparoscopic staging can be
valuable in certain gastrointestinal malignancies, a
wide variety of pre-DL staging modalities, imaging
techniques, follow-up, patient selection for DL and
surgery make interpretation of the data difficult. It
should again be stressed that factors independent
from imaging, staging or DL such as definitions of
resectability are critical to ascertaining the potential
value of DL in assessment of such resectability.
Despite these limitations, careful analysis of the
recent literature regarding the utility and limitations of
DL in the era of high-quality non-invasive imaging
permits the development of a rational approach to the
selective use of DL in staging of hepatic and biliary
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malignancies. The present review summarizes data in
this setting and stratifies the analysis into major dis-
ease areas including colorectal liver metastases,
hepatocellular carcinoma, and biliary cancers (extra-
hepatic cholangiocarcinoma and gall bladder carci-
noma) to provide a perspective on the role of DL in
staging hepatobiliary cancers.
Colorectal liver metastases
Resection criteria
Traditional criteria for resection of colorectal liver
metastases (CRCLM) have changed dramatically over
the past 10 years, and survival following resection has
nearly doubled. In fact, traditional barriers to resection
such as tumour size, tumour number and the pres-
ence of extrahepatic disease are dissolving, whereas
high-quality imaging, improving chemotherapy and
aggressive, safer resection approaches have led to 5-
year survival after complete resection of CRCLM of
53–58%.2–5 Even level 1 (periportal) lymph nodes that
are involved can be resected in selected cases at the
time of hepatic resection, providing acceptable long-
term survival.6 When such modern criteria are used,
by not limiting tumour size or number, but rather focus-
ing on complete resection of disease, the resectability
rate of patients taken to open surgery without DL can
exceed 90%7 with acceptable survival (53% at
5 years).
Patterns of spread and underlying liver disease
CRCLM represent secondary cancers, and tend to
occur in the background of an otherwise normal liver.
Thus, assessment of the underlying liver disease is
less important for this disease. Exclusion of unresec-
table extrahepatic disease and accurate identification
of all intrahepatic lesions is essential to determine
resectability. The liver remnant can be accurately
assessed with computed tomography (CT) volumetry8
to enable extended resection virtually without mortal-
ity.9 When found, additional liver lesions most often
lead to a change in operative plan, rather than aban-
donment of resection, particularly given the sensitivity
and specificity of modern spiral CT or positron-
emission tomography combined with CT (PET/CT) to
accurately define disease preoperatively.10,11 Increas-
ingly accepted techniques to enable safe resection
in patients who present with initially unresectable
bilateral liver metastases include downstaging
chemotherapy,12 two-stage resection13 and portal vein
embolization.14 Finally, surgical palliation is rarely indi-
cated for patients with unresectable CRCLM.
Recognizing the expanding indications for resec-
tion, improved imaging and presurgical patient selec-
tion, and improving outcome for resection of CRCLM,
the role for DL in selection for laparotomy in these
patients is small. Review of the limited existing litera-
ture supports this contention.15
Literature review
The  yield  of  DL  in  CRCLM  ranges  from  10–35%,
with accuracy as low as 25% and as high as 75%,
depending on preoperative imaging, selection for DL
and criteria for resectability. A minority of patients
avoid non-therapeutic laparotomy when DL is used
(Table 1).15–20 On the other hand, DL appears to be
most useful to identify peritoneal metastases, despite
limitations from adhesions. Detailed analysis of the few
studies that have examined the utility of DL for CRCLM
is warranted.
The first study that examined the utility of DL (com-
bined with LUS) in the selection of patients for resec-
tion of CRCLM does not report the selection criteria
for DL, but begins by suggesting that the approach is
feasible in most patients (92%).16 The yield for unre-
sectable disease was 36% of the total number of
patients intended for DL, and accuracy of DL was
75%. The authors proposed that LUS significantly
improved their ability to locate and characterize liver
lesions, whether metastases or benign lesions. Unfor-
tunately, the overall resection rate was only 52% of the
50 patients taken to surgery, which suggests subopti-
mal pre-DL imaging or poor patient selection for
surgery.
The importance of patient selection for DL was
emphasized in a subsequent study, which compared
24 patients selected for DL (because of a short dis-
ease-free interval from primary diagnosis or multiplic-
ity of metastases) with patients without these selection
criteria.18 The yield for DL in these selected ‘high-risk’
patients was similar to the yield in Rahusen’s report
(33%) with an identical accuracy (75%) for identifica-
tion of disease precluding resection. The resection
rate in the high-risk group (50%) matched the resec-
tion rate reported by Rahusen as well (52%), whereas
the resection rate was 94% in 49 patients without high-
risk criteria who did not undergo DL.
To further emphasize the importance of resection
criteria for resectability, Figueras published a letter in
response to Rahusen’s report.7 In his personal series
of 119 patients operated for CRCLM who did not
undergo DL, the resection rate was 91% and, thus, the
maximum proportion of patients who could have ben-
efited from DL was only 9%, rather than the 36%
proposed by Rahusen. Figueras reiterated that the
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reasons that patients in his personal series could not
undergo resection included unresectable extrahe-
patic metastases in five patients and intrahepatic
tumour location or extent that would prevent complete
hepatic resection in four patients. Figueras appropri-
ately reiterated and clarified the important point that
the number of tumours and tumour size criteria were
not used to define resectable and unresectable dis-
ease, and that in most cases when new findings were
discovered at laparotomy, the surgical plan was either
minimally altered or not altered and resection was
completed as planned. This approach led to the
expected survival rate for resection of CRCLM in mod-
ern series exceeding 50% at 5 years.5
In an attempt to clarify the indications for DL in
staging patients with CRCLM, a larger series was
reported by Grobmyer et al.19 which includes patients
from a prior study.17 Selection criteria for DL were not
reported, but the overall resection rate was 76%.
Among 264 patients selected for DL, only 64% under-
went complete DL. The yield in this study, after high-
quality imaging, was only 10% for unresectable
disease with an accuracy of 54% based on findings
at laparotomy in patients who were believed to be
resectable after DL. It is interesting to note that in the
study by Grobmyer et al., no patient determined to be
unresectable by DL required open surgical palliation,
although 15 patients with false negative DL required
open palliation – therefore 10% of patients who were
submitted to an attempt at DL were spared non-
therapeutic laparotomy by systematic use of DL. Anal-
ysis of the subgroup of patients considered to be at
high-risk for the presence of unresectable disease
using their previously published clinical risk score21
Table 1. Laparoscopic staging for colorectal liver metastases
Author, 
year
No. 
patients
Yield Accuracy Missed 
at DL
Spared non-
therapeutic  
laparotomy
Resection
rate
Comments 
Rahusen, 
199916
50 36% 75% 1 LN
5 Liver
36% 52% 94% underwent complete 
DL. Resection rate of 52% 
suggests poorly selected 
patients or excessively
strict resection criteria.
Jarnagin, 
200117
103* 14% 54% 4 LN
4 Peritoneal
4 Liver
10% 75% 67% underwent complete 
DL. *Patients included in 
Grobmyer, 2004, below.
Metcalfe, 
200318
24 selected† 33% 75% 1 LN 33% 50% 100% underwent complete
DL. †Selected for DL by
short disease free interval
from primary diagnosis,
multiple metastases.
49 N/A N/A 1 Peritoneal
2 Liver
N/A 94%
Grobmyer,
200419
264* 10% 54% 11 LN
5 Peritoneal
6 Liver
10% 76% 64% underwent complete
DL. No DL-unresectable
patient required open 
palliation, but 15 false negative 
DL required open palliation.
Yield dependent on CRS: 
0–1, 0%; 2–3, 11%; 4–5, 
24% yield. *Includes 
patients from Jarnagin, 
2001 above.
Koea, 
200420
59 5% 38% 2 LN
2 Peritoneal
1 Portal HTN
5% 78% 92% underwent complete 
DL.
De Castro, 
200415
43 DL 7% DL 25% 2 NR DL 7% 72% 74% underwent complete 
DL + LUS.
DL + LUS 12% DL + LUS 42% DL + LUS 19%
Yield: total number of patients proven to be unresectable at DL/total patients with attempted DL.
Accuracy: total number of patients proven to be unresectable at DL/total patients proven to be unresectable (i.e. those missed at 
DL, found at laparotomy).
CRS, colorectal score; DL, diagnostic laparoscopy; HTN, hypertension; LN, lymph nodes; LUS, laparoscopic ultrasound.
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suggested that subgroups with high-risk might benefit
more from DL than those with low-risk. Regarding the
disease that was missed at DL, consistent among
studies which report this factor is missed extrahepatic
lymph node involvement and despite the potential
advantage  of  DL  to  identify  peritoneal  disease  this
is consistently one of the sites DL under-evaluates
because of adhesions. Finally, factors related to either
lesions in the liver or their locations are frequently
missed at DL. Grobmyer et al. have been criticized for
suggesting that the addition of LUS significantly
improves the yield of staging DL16 because LUS find-
ings usually lead to a change in operative plan rather
than abandonment of resection.7 Furthermore, DL and
LUS were feasible in only 74% of the patients selected
for DL and ultrasound in another study, which might
further limit the utility of the modality.15
Recommendations
All published studies for DL in patients with CRCLM
are limited by the lack of definition of resectable
disease, and a statement on whether resectable
extrahepatic disease was a contraindication to
hepatic resection. Because of the recent advances in
diagnostic imaging, improvements in the safety of
extended and multistage resection, and more effective
chemotherapy, the role for DL in staging CRCLM
appears to be limited and probably declining. Resec-
tion rates exceeding 90% for patients taken to surgery
without DL support this contention. Available data
suggest that DL might have some utility only for
selected patients at highest risk for detection of unre-
sectable disease, particularly those who have not had
chemotherapy before surgery. At The University of
Texas M. D. Anderson Cancer Center in Houston,
USA, most patients have undergone chemotherapy
prior to surgery, DL is not used and the resection rate
is approximately 88% (unpubl. data).
Hepatocellular carcinoma
Resection criteria
Resection criteria for hepatocellular carcinoma focus
on both liver factors and tumour factors. When liver
function is preserved and portal hypertension is
absent, patients are considered for hepatic resection.
Most authors propose that 40% of the standardized
total liver volume must remain after resection when
significant fibrosis or cirrhosis are present,8,14,22 and
20% of the standard total liver volume must remain
after resection without cirrhosis.14,23 Patients who are
candidates for minor resection can be selected using
clinical factors combined with functional tests such as
indocyanine green retention.24 Preoperative portal
vein embolization should be used for selected patients
with an inadequate liver remnant volume.9,23,25
Factors that relate to outcome, including tumour
size and number, are overwhelmed by pathological
factors such as vascular invasion and the degree of
underlying liver fibrosis as determinants for survival,
and thus, determinants for resectability.26 Tumor size
is not a limiting factor, particularly in the absence of
major vascular invasion and no strict criteria have
been developed for tumour number and resectability,
as long as an adequate remnant can be left.27 For
patients with compensated liver function and ade-
quate liver remnant, 5-year survival following resection
of single tumours of any size (American Joint Commit-
tee on Cancer (AJCC)28 T1 classification tumours, sol-
itary without vascular invasion) is 55%, for T2 (solitary
tumour with vascular invasion or multiple tumours,
none > 5 cm) 37%, and for T3 (multiple tumours, any
> 5 cm or tumour(s) involving major branch of portal
or  hepatic  vein(s))  15%.26  It  is  interesting  to  note
that severe fibrosis decreases the survival for each T
classification.26 Current criteria for transplantation of
HCC are relatively unified around the world, although
these criteria are fairly simple, in that they are purely
morphological, based solely on tumour size and num-
ber. Patients with cirrhosis and a solitary HCC £ 5 cm
or up to three tumours £ 3 cm under a cutoff age
(generally 65–70 years) are generally considered to
be candidates for liver transplantation (Milano Crite-
ria).29 Large studies show that transplantation for these
indications can provide survival just over 60% at
5 years.30
Thus, accurate staging of both tumour and liver
greatly impacts selection of surgical treatment,
whether resection or transplantation, and further
impacts prognosis.
Patterns of spread and underlying liver disease
HCC occurs most often in the setting of fibrosis or
cirrhosis. The degree of cirrhosis impacts the sensitiv-
ity and specificity of pre-surgical imaging for HCC.
The highly nodular, cirrhotic liver can contain indeter-
minate hypervascular nodules not well characterized
on pretreatment imaging.31–33 Patients with severely
nodular livers are usually not candidates for resection;
therefore, the problem of indeterminate nodules might
be a lesser problem for resection candidates versus
transplantation candidates. High quality multiphase
CT imaging, CT arterial portography and CT hepatic
arteriography, as well as multiphasic MRI enable
improved lesion detection down to 0.2 cm,32,34,35
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although correct characterization of lesions <1–2 cm
can be difficult.36,37 PET has virtually no utility in detect-
ing primary HCC.38
In addition, HCC has a tendency to invade major
vascular structures (hepatic veins, portal veins), which
significantly impacts not only outcome but also appro-
priateness of resectional treatment or transplantation.
In fact, vascular invasion found at imaging is an
absolute contraindication to transplantation, whereas
highly selected patients with major vascular invasion
can benefit from resection.
Given that there is virtually no surgical palliation that
can be offered for patients with HCC, an approach that
would limit the number of non-therapeutic laparoto-
mies is highly desirable and, clearly, that approach
must aid in characterization of the existing tumours,
their location and intrahepatic/intravascular extent,
identification of additional tumour nodules, character-
ization of indeterminate nodules, and characterization
of underlying liver disease and planned remnant for
resection. Carcinomatosis is a rare finding in HCC
when accurate staging is used.39,40
Thus, accurate detection and characterization of
lesions and assessment of the presence and
extent of vascular invasion would be the primary
goals of prelaparotomy or pretransplant staging DL
(Table 2).
Literature review
The first study of DL in the era of modern liver imaging
comes from Hong Kong. Lo et al. examined 91
patients in whom DL and LUS were carried out imme-
diately prior to laparotomy in patients carefully
selected for surgery using percutaneous ultrasound,
spiral or lipiodol CT and hepatic arteriogram, and
assessment of liver function based on Child–Pugh rat-
ing and indocyanine green retention.41 The DL yield
for definitive assessment of unresectability was 16%,
with an accuracy of 63%. Specifically, 15/91 patients
were found at DL to have unresectable disease and
an additional nine patients were found at laparotomy
to have unresectable disease such that 74% of all
patients staged with DL underwent complete resec-
tion of their disease. Thus, using DL, 16% of patients
were spared non-therapeutic laparotomy. Careful
analysis of their data suggested that the laparoscopic
staging was most likely to fail to accurately identify
unresectable disease in patients with tumours
> 10 cm, was found to underestimate invasion of
extrahepatic organs (T4 classification lesions) and to
underestimate the degree of major vascular invasion.
Conversely, DL was highly useful in assessment of the
liver remnant.
Another recent study examined patients with hepa-
tocellular carcinoma thought to be resectable based
on modern imaging reviewed at a multidisciplinary
case conference.42 This was not a randomized study
and according to the authors’ description, the deci-
sion to carry out DL was left to the discretion of the
operating surgeon, with some in their group almost
routinely using DL and others who virtually never used
DL; thus the specific criteria on which the patients
were laparoscoped is not clear. The overall yield for
60 patients intended for DL was 24% (DL was incom-
plete in one patient), accuracy was 74% (14/19
patients with unresectable disease were diagnosed
by DL). In all, 22% were spared non-therapeutic lap-
arotomy. DL was most helpful in assessment of the
extent of cirrhosis, but missed peritoneal disease in
one patient and involved lymph nodes in two patients,
underestimated the extent of vascular invasion in one
patient and missed the presence of one additional
tumour in one patient, suggesting the limitations of DL
even in this setting. Without particular selection criteria
clearly stated for resection or for DL, it is difficult to
generate recommendations based on these data,
although some of the deficiencies of DL for HCC are
underscored based on ‘missed’ findings at DL.
An interesting study examined the utility of DL in
assessment of ruptured hepatocellular carcinoma for
resectability. In the study from Lang et al., 33 patients
underwent DL with LUS prior to laparotomy for resec-
tion of a ruptured hepatocellular carcinoma.43 These
were compared to 26 patients who went directly to
laparotomy with the similar preoperative characteris-
tics to the DL group. The laparoscoped patients had
a 36% yield of DL, proving unresectable disease (12/
33 patients were unresectable) and an accuracy of
92% (12/13 patients) based on subsequent laparot-
omy which showed only one patient with metastatic
disease not defined at DL. Interestingly, the overall
resection rate for the laparoscoped group was 20/33
patients or 61%, whereas in those who went directly
to laparotomy, the resection rate was 18/26 patients,
or 69%, which confirms that the populations com-
pared were similar. DL enabled 36% of the patients in
that group to avoid non-therapeutic laparotomy; only
one patient thought to be resectable at DL was found
at laparotomy to have unresectable disease (LUS
underestimated extent of tumour thrombus extending
through the hepatic vein into the vena cava). Although
the addition of LUS to DL was feasible in most patients
and complimented pre-DL imaging to characterize
small nodules as benign or malignant, even those
findings did not necessarily lead to abandonment of
hepatic resection, but rather, effected change in the
operative plan.44
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One paper recently examined the utility of DL to
stage candidates for liver transplantation with Child’s
C cirrhosis and HCC based on specific selection
criteria. Patients in whom intrahepatic lesions had
indeterminate size or borders, in whom there was an
indeterminate number of lesions and serum an alpha-
fetoprotein was <100 ng/mL, underwent DL, LUS,
biopsy and/or tumour ablation.45 Of the 18 patients
who underwent attempted DL, four of the first six but
none of the subsequent 12 patients were converted to
an open procedure, which suggests a learning curve
for DL in patients with advanced cirrhosis. In all, 12
patients had significant changes in their staging
based on DL; six were downstaged (of whom four
ultimately went to transplantation). All four of the trans-
planted patients had confirmation of accurate laparo-
scopic staging based on pathological analysis of the
explanted specimens. An additional six patients were
upstaged, some for multiple reasons. Two were found
to have advanced disease, three were upstaged
based on biopsy and seven had a change in the
number or size of lesions based on operative
Table 2. Laparoscopic staging for hepatocellular carcinoma
Author, 
year
No. 
patients
Yield Accuracy Missed 
at DL
Spared non-
therapeutic
laparotomy 
Resection
rate
Comments 
Lo, 199841 91
DL + LUS
16% 63% 1 liver 
assessment,
4 MVI, 3 T4
16% 74% DL + LUS primarily underestimated 
extent of portal/hepatic venous/caval 
or extrahepatic extension.
Conclude: DL is limited when tumor 
≥10 cm, for T4 tumors, and in MVI, but 
DL assesses adequacy of liver 
remnant accurately.
Weitz, 
200442
60 23% 74% 2 LN
1 MVI
1 Peritoneal
1 Liver
22%* 67%* *Despite new findings in 20 patients 
(33%), resection was possible. In 
13 others (22%) laparotomy was 
avoided (1 additional patient deemed 
unresectable was treated with open 
cryotherapy).
Yield 30% in patients with clinical
cirrhosis, MVI or bilateral tumors; DL 
recommended in this subset.
Ruptured HCC
Lang, 200443 33 36% 92% 1 MVI 36% 61% DL highly effective in identifying
DL + LUS
26 open N/A N/A N/A 69%
unresectable patients following 
rupture of HCC.
Selected liver transplant candidates with HCC
Kim, 200445 18
DL + LUS
67% Four of first 6 but none of subsequent 
12 patients converted DL to open 
laparotomy.
Six down-staged of which 4 
transplanted, pathology of explant 
confirmed DL staging in all 
transplanted.
Staging changed by DL on finding 
2 with advanced disease, 7 with 
change in tumor size/number at LUS, 
3 as a result of DL guided biopsy.
13 patients treated with ablation at the 
time of surgery (12 radiofrequency, 
1 ethanol).
Yield: total number of patients proven to be unresectable at DL/total patients with attempted DL.
Accuracy: total number of patients proven to be unresectable at DL/total patients proven to be unresectable (i.e. those missed at 
DL, found at laparotomy).
DL, diagnostic laparoscopy; HCC, hepatocellular carcinoma; LN, lymph nodes; LUS, laparoscopic ultrasound; MVI, major vascular 
invasion (portal or hepatic venous, including vena cava).
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ultrasonography. Finally, 13 of the total patients under-
went ablation of their liver tumour(s) at laparoscopy or
laparotomy. Complications occurred in two patients,
one of whom required a 2-unit transfusion of blood and
one who died on postoperative stay day 7 because of
gastrointestinal bleeding, which further emphasizes
the importance of proper patient selection for surgical
staging in patients with the complex mix of cancer and
severe underlying liver disease. Thus, laparoscopic
staging for HCC in patients with cirrhosis and equivo-
cal preoperative radiological and clinical findings
might accurately stratify candidacy for transplantation.
Furthermore, the advent of ablative therapies for
selected patients in whom resection is not an option
because of inadequate liver reserve might further
expand the role for DL in the staging of patients who
are candidates for anaesthesia and surgery.
Recommendations
DL and LUS enable direct visualization of the liver,
improve evaluation of intrahepatic extent of liver
tumours and might facilitate non-resectional therapies.
Encouraging results for laparoscopic staging of pri-
mary liver tumours suggests that the role for DL in this
disease might be growing for selected patients, par-
ticularly in those patients with marginal liver remnants,
cirrhosis, indeterminate nodules and previously rup-
tured tumours. The role for DL in transplant candidates
with equivocal staging is emerging.
Extrahepatic biliary cancer
Hilar cholangiocarcinoma: resection criteria, 
patterns of spread and underlying liver disease
Extrahepatic biliary carcinomas present a different set
of problems than HCC or CRCLM, mainly because of
the different pattern of spread (tendency to metasta-
size to regional portal lymph nodes, but also aorto-
caval lymph nodes). Peritoneal metastasis is a
problem, but occurs less frequently. Patients without
those problems have other local issues, including vas-
cular encasement of the extrahepatic-hepatic artery
and portal vein, intrahepatic metastases and, impor-
tantly, intrabiliary extension. Underlying liver disease
(cirrhosis) is not a major issue in this disease, however,
liver remnant volume is critically linked to postresec-
tion complications.9,14
Using modern techniques, cholangiocarcinoma can
be staged with increasing accuracy, using a combi-
nation of cross-sectional studies and studies to exam-
ine intrabiliary extent.46 Multiphase helical CT, using
modern techniques, has an overall accuracy of 76–
100% for staging cholangiocarcinoma.47,48 MRI and
magnetic resonance arteriography (MRA) have an
overall accuracy of approximately 89% for extrahe-
patic cholangiocarcinoma.48,49 These studies assess
vascular structures, the hepatic parenchyma and the
local tumour, but are complimented by longitudinal
assessment of biliary involvement using magnetic
resonance cholangiopancreatography (MRCP), and
invasive techniques including endoscopic retrograde
cholangiopancreatography (ERCP) and percutaneous
transhepatic cholangiography (PTC). Although accu-
rate determination of the biliary extent of cholangio-
carcinoma is essential, even the ‘gold standard’ is not
perfect. Accuracy for PTC in prospective comparison
with MRCP and ERCP remains best among the three
(53% vs 26% vs 29%), but ERCP and MRCP overes-
timate biliary extension in nearly 40% of patients.50
Newer modalities such as PET51 and intrabiliary
MRI52 are emerging to improve detection of extrahe-
patic disease and intrabiliary extension. Despite these
advanced staging studies, modern series using opti-
mal prelaparotomy staging show that 25–40% of
patients are found to have unresectable disease at the
time of surgery, and thus, laparoscopy is being inves-
tigated to improve this resectability rate.
Hilar cholangiocarcinoma: literature review
A series of studies that examine the utility of laparo-
scopic staging for extrahepatic cholangiocarcinoma,
though small, are quite helpful in determining which
patients might benefit from this staging approach
(Table 3). The first is a small study from Martin et al.
that examined 26 patients with extrahepatic cholang-
iocarcinoma.53 All six patients with suspected
metastases had that disease confirmed for a 100%
yield for this subset, enabling all of those patients to
avoid non-therapeutic laparotomy. Of the 20 patients
who were thought to be resectable based on high-
quality prelaparotomy imaging, the yield of DL was
25% with an accuracy of only 30%, with the most
common cause for false negative DL being intrahe-
patic or local extension of the disease. Of note was
that cytology failed to identify more than a quarter of
the patients who actually had macroscopic metastatic
disease. The authors noted that percutaneous biliary
drainage did not appear to increase the risk of perito-
neal contamination.
A larger study from Amsterdam examined 110
patients with cholangiocarcinoma.54 Patients deemed
resectable based on high-quality imaging were sub-
jected to DL and 41% were found to have unresect-
able disease. The accuracy was 60%; failings of DL
included underestimation of intrahepatic or local dis-
ease extent. LUS added little to the DL in terms of
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assessment of these patients because of its limitations
in accurately identifying local disease extent, the
major factor that impacts resectability in patients
deemed resectable after prelaparotomy imaging.
Finally, a study including 56 patients with cholang-
iocarcinoma examined the utility of DL based on the
T classification of the primary tumour.55 It was found
that the yield for DL in patients with T2 and T3 classi-
fication tumours was 36%, but the yield for T1 tumours
was only 9%. For the entire group, DL yield was 25%
with an accuracy of 58%. Again, the major deficit of
DL was found to be assessment of biliary disease and
local extent of tumour. In addition, a substantial num-
ber of patients with extrahepatic nodal metastases
were missed at DL.
Gall bladder carcinoma: resection criteria, patterns 
of spread and underlying liver disease
Although resectability for advanced gall bladder car-
cinoma is defined in a fashion similar to hilar cholan-
giocarcinoma, gall bladder cancer has a strong
propensity to recur in the peritoneal cavity and surgi-
cal incisions, as well as locoregional and distant (aor-
tocaval) lymph nodes.56,57 This disease tends to occur
in patients without underlying liver disease. Early can-
cer is treated with less radical surgery. Furthermore,
a substantial proportion of resectable gall bladder
carcinomas are identified only after pathological anal-
ysis of the gall bladder resected by DL, or diagnosed
at DL for cholecystectomy for presumed benign indi-
cations,58 and gall bladder rupture at the time of
cholecystectomy is a risk factor for peritoneal dissem-
ination and port-site recurrence. It is widely accepted
that a strictly laparoscopic approach to very early
stage gall bladder cancers (in situ carcinoma and T1a
tumours, i.e. tumours limited to the mucosa), with
cholecystecomy only, is adequate treatment (provided
that the cystic duct margin is negative for tumour)
because of the low incidence of nodal metastases for
T1a classification tumours (2.5%).59 Some groups
advocate cholecystectomy only adequate for T1b
tumours (invading muscular layer),60 though most rec-
ommend extended cholecystectomy because of the
associated 15% incidence of nodal metastases for
T1b tumours.59
Table 3. Laparoscopic staging for extrahepatic biliary carcinoma (hilar cholangiocarcinoma [CCA] and gall bladder carcinoma [GB])
Author, 
year
No. 
patients
Yield Accuracy No. missed
at DL
Spared non-
therapeutic  
laparotomy
Resection
rate
Comments 
Martin, 
200153
26 CCA
6: ?metastasis
20: resectable
42%
100%
25%
73%
100%
30%
1 LN
3 Liver/local
42%
100%
42%
42%
0%
55%
Cytology missed 9 patients with 
macroscopic metastatic disease.
Percutaneous drainage did not 
appear to increase risk for 
peritoneal contamination.
Tilleman, 
200254
110 CCA 41% 60% 2 LN
27 Liver/local
1 Benign dz
41% 32% Recommend DL for CCA but 
remarks that LUS adds little to DL.
Weber, 
200255
56 CCA 25%* 58% 5 LN
2 Peritoneal
12 Liver/local
36% *CCA YIELD: T2/3 = 36%; 
T1 = 9%.
44 GB 48% 42% 3 LN
1 Peritoneal
11 Liver/local
33% of total† 25% †2 patients with unresectable 
disease at DL underwent open 
palliation; not specified whether 
CCA or GB.
Recommend DL for GB and T2/3
CCA.
Vollmer, 
200272
23 CCA 17% 57% 2 LN
1 Liver + 
peritoneal
17% 70% Utility of DL depends on 
diagnosis; recommend DL for gall 
bladder carcinoma.
11 GB 55% 86% 1 LN + local 55% 27%
Yield: total number of patients proven to be unresectable at DL/total patients with attempted DL.
Accuracy: total number of patients proven to be unresectable at DL/total patients proven to be unresectable (i.e. those missed at 
DL, found at laparotomy).
DL, diagnostic laparoscopy; dz, disease; LN, lymph nodes; LUS, laparoscopic ultrasound; ?metastasis, metastasis suspected but 
not definitive on prelaparoscopy imaging.
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T2 gall bladder cancer warrants extended chole-
cystectomy including at least partial resection of the
liver (segments IVb and V) with regional lym-
phadenectomy; the bile duct must be resected when
the cystic duct margin is involved with the tumour. This
approach is generally accepted because of the high
incidence of regional nodal metastasis (56% for T2
cancers) and the improvement in survival with this
approach over lesser surgery.61–64
Major resections for more advanced tumours (T3,
T4) with right or extended right hepatectomy or pan-
creaticoduodenectomy are indicated. Radical resec-
tion can lead to survival rates between 21% and 44%
at 5 years for advanced tumours. The extent of
hepatic resection is determined by the extent of
tumour invasion into the gall bladder fossa and the
extent of involvement of the right portal triad and
segment IV.63,65,66 Resection of the extrahepatic bile
duct is probably necessary for both clearance of
tumour due to invasion of the hepatoduodenal liga-
ment in more than 40% of patients with advanced
gall bladder cancer67 and to effect a complete portal
lymphadenectomy. Finally, extent of the disease to
the aortocaval lymph nodes has been shown to be
such a poor prognostic indicator that many groups
biopsy these nodes before continuing with a major
hepatectomy.68
Gall bladder carcinoma: literature review
Two studies have specifically examined the role for
laparoscopy in staging patients with gall bladder car-
cinoma. The most widely quoted is from Weber et al.
in which 44 patients with gall bladder carcinomas
were staged with laparoscopy. Among these, the yield
was 48% for DL and the accuracy 42%. Laparoscopy
missed three patients with nodal metastases, one
patient with peritoneal metastases, nine patients with
locally advanced tumours and two patients with liver
metastases. It was quite effective at identifying the
greater proportion of patients with peritoneal disease.
Despite these deficiencies, non-therapeutic laparot-
omy was avoided in one-third of the patients who were
deemed resectable after high-quality imaging using
DL.55
The only other study that has examined the utility
of DL is from Vollmer et al. in which 11 patients
underwent laparoscopy prior to exploration for radio-
graphically resectable gall bladder carcinoma. The
yield on their study was similar to Weber’s study
(55%), although the accuracy was slightly higher
(86%). In all, 55% of the patients with metastatic dis-
ease were able to avoid non-therapeutic laparot-
omy.72 The high incidence of peritoneal disease
makes patients with gall bladder cancer likely to ben-
efit from DL.
Recommendations: extrahepatic biliary carcinoma
Integrating data regarding the limitations of cross-
sectional imaging with CT and MRI with the accuracy
of estimation of biliary extent of disease prior to sur-
gery, and analysis of the available data with regards
to laparoscopy for extrahepatic biliary carcinoma
suggests that DL might be useful for patients with
advanced disease and have a lesser role for patients
with earlier-stage disease. For gall bladder cancer,
especially in patients with T3 or greater tumours or
rupture of the gall bladder at cholecystectomy, DL is
warranted. Indications for DL in early stage gall blad-
der cancer are not yet clear.
Other advantages and disadvantages of 
diagnostic laparoscopy
Serious complications of DL are reported in a minority
of reviewed series, but the incidence appears to be
low (0–3%), including injury to visceral structures
requiring laparotomy, bleeding and infection.41,54,55
Port-site metastases following staging laparoscopy
are anecdotal and did not occur in the series of
patients who underwent DL for ruptured hepatocellu-
lar carcinoma.43 In a report of 395 patients who under-
went staging laparoscopy for a variety of upper
gastrointestinal malignancies not related to the liver,
the total reported port-site recurrence rate was 2%
and appeared to be associated with biopsy of
unresectable tumours.69 Thus, neither port-site implan-
tation nor surgical complications appear to contrain-
dicate DL for liver tumours.
Certainly, limitations of laparoscopy include the fact
that manual and digital palpation is not possible, lap-
aroscopic dissection for tumours in the vicinity of the
great vessels might not be safe, wide mobilization and
displacement of the liver is limited, and angles for
laparoscopic ultrasound can be limited, especially for
evaluation of the retrohepatic vena cava.41 Advanced
laparoscopic techniques such as creating a ‘window’
in the falciform ligament to facilitate laparoscopic
ultrasound16 and infusion of saline for ‘underwater’ lap-
aroscopy,70 as well as other advanced techniques,71
might enhance evaluation of the liver. Finally, laparos-
copy might reduce hospital costs and hospital stay for
patients in whom laparotomy is avoided.17,20
Summary and recommendations
The role for DL is evolving for hepatobiliary malignan-
cies. Advances in imaging, evolving definitions of
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resectability and improved surgical techniques, as well
as more effective systemic therapy, have impacted the
potential additive benefit of staging DL after modern
presurgical imaging, although deficiencies persist.
For colorectal liver metastases, the role for DL is
limited and probably decreasing as more patients
become candidates for complete resection of meta-
static disease using multistage resection techniques,
portal vein embolization, downstaging chemotherapy
and aggressive techniques to resect extrahepatic
disease. The role for DL in these patients is reserved
primarily for those with suspicious, but not definitive,
imaging findings that would preclude resection of
extensive extrahepatic disease, nodal disease or dif-
fuse bilateral metastases not amenable to multistaged
resection.
For patients with hepatocellular carcinoma, DL
appears to compliment cross-sectional imaging stud-
ies, particularly in evaluation of the extent of cirrhosis,
and might facilitate characterization of nodules in the
planned remnant liver. Although limitations might exist
with regard to the ability of DL and LUS to evaluate
the extent of major vascular invasion, sufficient evi-
dence exists to show that selected patients with
advanced tumours, particularly those with cirrhosis or
with ruptured HCC, might benefit significantly from DL
and avoid non-therapeutic laparotomy. DL is likely to
be less useful for patients without cirrhosis. In patients
with equivocal pretransplant staging imaging for
hepatocellular carcinoma, laparoscopy might have an
emerging role.
Finally, for extrahepatic biliary cancer, DL is indi-
cated primarily for patients with advanced disease.
This includes most patients with gall bladder cancer
because of the tendency of this disease to metasta-
size to the peritoneal cavity, as well as patients with
advanced stage hilar cholangiocarcinoma. System-
atic DL for hilar cholangiocarcinoma appears to be of
limited value.
Thus, despite the limitations of DL, this modality
clearly has a role in staging patients with equivocal
findings on high-quality presurgical imaging, but for
most patients with hepatobiliary cancer deemed
resectable on imaging, DL might be useful in a limited
group of patients with advanced disease or marginally
resectable tumours.
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